Abstract:ETHNOPHARMACOLOGICAL RELEVANCE:Polysaccharides and small molecules commonly co-exist in decoctions of traditional Chinese medicines (TCMs). Our previous study outlined that ginseng polysaccharides (GP) could interact with co-existing ginsenosides to produce synergistic effect in an over-fatigue and acute cold stress model via gut microbiota involved mechanisms.AIM OF THE STUDY:This study aimed to verify the interactions by examining the impact of GP on oral pharmacokinetics of ginsenoside Rb1 (Rb1), the dominant protopanoxadiol (PPD)-type ginsenoside in Ginseng, on a dextran sulphate sodium (DSS) induced experimental colitis model which was characterized by gut dysbiosis, and to delineate the underlying mechanisms in vitro.MATERIALS AND METHODS:Rats received drinking water (normal group), 5% DSS (UC group), or 5% DSS plus daily oral administration of GP (GP group) for 7 days and fecal samples were collected on day -3, 0 and 6. On day 7 all animals received an oral dosage of Rb1 and blood samples were withdrawn for pharmacokinetic study. The in vitro metabolism study of Rb1 in gut microbiota from normal and UC rats and the transport study of Rb1 across Caco-2 cell monolayer were carried out in presence/absence of GP. Rb1 and its bacterial metabolites ginsenoside Rd (Rd), ginsenoside F2 (F2), Compound K (CK) and PPD were determined using LC-MS/MS. Total and target bacteria in fecal samples were determined by using 16S rRNA-based RT-PCR. β-Glucosidase activity was determined by measuring 4-nitrophenol formed from 4-nitrophenyl-β-D-glucopyranoside hydrolysis.RESULTS:DSS induction did not alter AUC0-t and Cmax of Rb1, which, however, were doubled together with elevated AUC0-t of the metabolites, in particular Rd and CK, in GP group. GP influenced the microbial composition and showed a prebiotic-like effect. Accordingly, GP treatment could partially restore the β-glucosidase activity which was reduced by DSS induction. The presence of GP resulted in quicker microbial metabolism of Rb1 and higher Rd formation in first 8 h of incubation, while the impact on F2 and CK formation/conversion became obvious after 8 h. More interestingly, GP slightly stimulated Caco-2 cell growth and facilitated Rb1 transport across the Caco-2 monolayer in both directions, increasing the Papp of Rb1 from 10-7 cm/s to 10-6 cm/s.CONCLUSIONS:GP alleviated DSS-induced colitis-like symptoms and enhanced the systemic exposure of Rb1 through enhancing microbial deglycosylation and intestinal epithelial absorption of Rb1. These findings further demonstrated the important role of gut microbiota in the multifaceted action of polysaccharides in the holistic actions of traditional decoction of TCMs.

Impact of ginsenoside Rb1 on gut microbiome and associated changes in pharmacokinetics in rats

[Comparison Between the Characteristics of Absorption and Pharmacokinetic Behavior of Ginsenoside Rg1 and Ginsenoside Rb, of Panax Notoginseng Saponins].

Qualitatively and quantitatively investigating the metabolism of 20(S)-protopanaxadiol-type ginsenosides by gut microbiota of different species

Ginsenoside Rb1 ameliorates Glycemic Disorder in Mice With High Fat Diet-Induced Obesity via Regulating Gut Microbiota and Amino Acid Metabolism

Effects of Broad-Spectrum Antibiotics on the Metabolism and Pharmacokinetics of Ginsenoside Rb1: a Study on Rats׳ Gut Microflora Influenced by Lincomycin.

Ginsenoside Rb1 Improves Metabolic Disorder in High-Fat Diet-Induced Obese Mice Associated With Modulation of Gut Microbiota

Ginseng Polysaccharides Enhanced Ginsenoside Rb1 and Microbial Metabolites Exposure Through Enhancing Intestinal Absorption and Affecting Gut Microbial Metabolism.

Comprehensive Multiomics Analysis of the Effect of Ginsenoside Rb1 on Hyperlipidemia

Combined Contribution Of Increased Intestinal Permeability And Inhibited Deglycosylation Of Ginsenoside Rb1 In The Intestinal Tract To The Enhancement Of Ginsenoside Rb1 Exposure In Diabetic Rats After Oral Administration

Prebiotics enhance the biotransformation and bioavailability of ginsenosides in rats by modulating gut microbiota

In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota

Comparative Analysis on Microbial and Rat Metabolism of Ginsenoside Rb-1 by High-Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry

Ginsenoside Rb1 Exerts Neuroprotective Effects Through Regulation of Lactobacillus Helveticus Abundance and GABAA Receptor Expression

Dmd064881 1702..1710

Comparative analysis of the gut microbiota in people with different levels of ginsenoside Rb1 degradation to compound K

Ginsenoside Rb1 protects against diabetes-associated metabolic disorders in Kkay mice by reshaping gut microbiota and fecal metabolic profiles

Pharmacokinetic Profiling of Ginsenosides, Rb1, Rd, and Rg3, in Mice with Antibiotic-Induced Gut Microbiota Alterations: Implications for Variability in the Therapeutic Efficacy of Red Ginseng Extracts

Ginsenoside Rk3 Alleviates Gut Microbiota Dysbiosis and Colonic Inflammation in Antibiotic-Treated Mice.

Gut Microbiota Composition in Relation to the Metabolism of Oral Administrated Resveratrol

Metabolic Characteristics of Ginsenosides from Panax Ginseng in Rat Feces Mediated by Gut Microbiota.

Effect of Long-Term Intake of Ginseng Extracts on Gut Microbiota in Rats